Belay closely monitors the allergy and emergency regulatory landscape and can confidently say that the 2025-2026 legislative cycle marks a watershed moment for food allergy safety in the United States. We are witnessing a fundamental shift from voluntary “best practices” to mandatory, statutory requirements that span from the local school cafeteria to the highest levels of federal oversight. For organizations and families alike, staying ahead of these changes isn’t just about compliance—it’s about creating an environment where safety is the default, not the exception.
A Landmark Year for Student Safety
The most significant federal update arrived on January 14, 2026, when the Protecting Children with Food Allergies Act was signed into law. This bipartisan legislation transforms how school food service personnel are trained. Historically, allergy training was often optional under USDA programs. Now, annual training on preventing, recognizing, and responding to allergic reactions is mandatory for all staff participating in the National School Lunch and School Breakfast Programs.
This federal momentum mirrors the continued expansion of Elijah’s Law across the states. Originally a New York initiative, we’ve seen critical progress in Arkansas with the signing of Act 865 in April 2025, which establishes statewide anaphylaxis policies for childcare facilities. Pennsylvania also took a major step, with the House passing similar bipartisan legislation in June 2025. These laws ensure that our youngest children are protected by staff who are not only trained to recognize symptoms but are also equipped with the medication to treat them.
The Restaurant Revolution: Transparency on the Menu
For the first time, we are seeing the “back of the house” brought into the light through state-level restaurant mandates. California’s Allergen Disclosure for Dining Experiences (ADDE) Act (SB 68), signed in October 2025, is a first-in-the-nation mandate. Effective July 1, 2026, restaurant chains with 20 or more locations nationwide must provide written allergen disclosures for the “Top 9” allergens directly on their menus or via accessible digital formats.
New York followed suit in November 2025 with A6558, which targets a long-standing loophole: food prepared and packaged on-site. Whether it’s a grab-and-go sandwich at a deli or a campus snack, New York now requires clear labeling of the Top 9 allergens. These laws represent a move toward radical inclusion, allowing consumers to make informed choices without the anxiety of an “unintended” ingredient.
Pharmaceutical Innovation and Economic Access
The clinical landscape has been equally transformative. The FDA’s approval of neffy, the first needle-free epinephrine nasal spray, has changed the “response” side of the equation. Following the 2mg approval in August 2024, the FDA approved the 1mg dose on March 5, 2025, for younger children weighing between 33 and 66 pounds. To ensure this technology reaches those who need it, the neffyinSchools program launched in January 2025, providing free doses to eligible K-12 schools nationwide.
In tandem, New York’s A05392 has updated the legal definition of “epinephrine device” to include these non-injectable formats. This allows schools and public venues to stock the delivery method that best suits their population, significantly reducing the “hesitation gap” for those with needle phobias.
However, innovation is only effective if it is affordable. The reintroduction of the EPIPEN Act on September 4, 2025, aims to cap out-of-pocket costs for a two-pack of epinephrine at $60 for most insured patients. Crucially, this updated bill is “delivery-neutral,” meaning it covers auto-injectors, nasal sprays, and sublingual films alike.
Regulatory Refinement and Global Context
Even our definitions are evolving. In January 2025, the FDA released its updated Edition 5 labeling guidance, which notably removed coconut from the list of tree nuts requiring mandatory allergen labeling. While companies can still voluntarily list it, this change aligns US policy more closely with scientific evidence regarding clinical cross-reactivity.
Finally, we look to the UK’s progress with Benedict’s Law as a global benchmark. The UK government’s commitment in February 2026 to publish mandatory statutory guidance for schools by September 2026 mirrors the shift we are seeing here: a move away from a “postcode lottery” of safety toward a universal standard of care.
The SME Perspective
At Belay, we see these updates as a call to action. The transition from 2025 into 2026 isn’t just a list of new rules—it is the construction of a comprehensive safety architecture. The era of “guessing” about allergens is ending; the era of informed, accessible safety is here.
